CORE-013: PROTEOMICS SHARED RESOURCE (PSR) PROJECT SUMMARY / ABSTRACT The OSUCCC Proteomics Shared Resource (PSR) provides CCSG investigators access to advanced mass spectrometry (MS) instrumentation, ancillary instrumentation for sample preparation, and expert staff to enable proteomic research, including data analysis. Two tenured faculty experts in mass spectrometry and proteomics, Drs. Michael Freitas (MBCG) and Vicki Wysocki, serve as PSR Director and Senior Faculty Advisor, respectively. They provide scientific leadership to the PSR with expertise in cancer proteomics, protein chemistry, bioinformatics, and mass spectroscopy methods development. The PSR offers numerous proteomics services to users that fall under the categories of protein identification, characterization, and quantification. The ability to confidently identify proteins is the central role of the PSR. Examples of protein characterization analysis include: identification of post-translational modifications, alternate splice forms, de novo protein sequencing and protein-protein interaction analysis.
The Specific Aims of the PSR are to: 1) provide advanced mass spectrometry based proteomics services; 2) provide innovative proteomic data analytics and bioinformatics platforms; and, 3) provide consultations with investigators on experiment design and train users on the operation of several self-operated MS instruments within the shared resource. Over the last grant period, there have been substantial upgrades to equipment in the PSR. Early in the grant period, three mass spectrometers were acquired with the help of federally funded awards: a Bruker Maxis Q-TOF, a Bruker UltrafleXtreme MALDI TOF-TOF, and a Bruker AmaZon ion trap with electron transfer dissociation (ETD). This year, three additional mass spectrometers, two high-end instruments (a Thermo Orbitrap Fusion and a Bruker 15 T FTICR along with a Thermo Quantiva triple quadrupole for targeted (MRM) analyses) are to be installed in the PSR with funding from two NIH S10 awards and also OSUCCC and other institutional support. These state-of-the-art MS instruments will improve services offered to OSUCCC members by providing significantly higher throughput shotgun proteomics, improved post-translational modification analysis, improved isotopic fine structure analysis for metabolomics, and greater capacity and data quality. The PSR has supported 37 OSUCCC members from all five OSUCCC research programs including 1 K24, 1 N01, 8 P01s, 2 P50s, 19 R01s, 8 R21s, 2 RC2s, 1 T32, and 2 U01s. The PSR has also contributed to over 74 OSUCCC member publications during the last grant period, 11 of which were in publications with a journal impact factor >10. The future plans for the PSR involve a constant effort to develop and adopt new innovative techniques and methods for protein analysis, and to acquire state-of-the-art mass spectrometry and chromatography instrumentation. Specifically, the PSR will fully integrate the 3 recently purchased major instruments, to introduce methods for 2-dimensional and 3-dimensional chromatography, and provide proteogenomics data integration. The PSR leverages extensive institutional support, and seeks only 14.2% support from CCSG funds. The Proteomics Shared Resource is part of the Analytics Grouping.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA016058-42S1
Application #
9632753
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Marino, Michael A
Project Start
Project End
Budget Start
2017-12-01
Budget End
2018-11-30
Support Year
42
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Ohio State University
Department
Surgery
Type
Schools of Medicine
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Nakashima, Hiroshi; Alayo, Quazim A; Penaloza-MacMaster, Pablo et al. (2018) Modeling tumor immunity of mouse glioblastoma by exhausted CD8+ T cells. Sci Rep 8:208
Coss, Christopher C; Clinton, Steven K; Phelps, Mitch A (2018) Cachectic Cancer Patients: Immune to Checkpoint Inhibitor Therapy? Clin Cancer Res 24:5787-5789
Rogers, Kerry A; Huang, Ying; Ruppert, Amy S et al. (2018) Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia. Blood 132:1568-1572
Eisfeld, Ann-Kathrin; Kohlschmidt, Jessica; Mrózek, Krzysztof et al. (2018) Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies. Leukemia 32:1338-1348
Burton, Jenna H; Mazcko, Christina; LeBlanc, Amy et al. (2018) NCI Comparative Oncology Program Testing of Non-Camptothecin Indenoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma. Clin Cancer Res 24:5830-5840
Salzer, Wanda L; Burke, Michael J; Devidas, Meenakshi et al. (2018) Toxicity associated with intensive postinduction therapy incorporating clofarabine in the very high-risk stratum of patients with newly diagnosed high-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group study AALL1131. Cancer 124:1150-1159
Yu, Peter Y; Lopez, Gonzalo; Braggio, Danielle et al. (2018) miR-133a function in the pathogenesis of dedifferentiated liposarcoma. Cancer Cell Int 18:89
Eisfeld, Ann-Kathrin; Kohlschmidt, Jessica; Mrózek, Krzysztof et al. (2018) NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcome. Leukemia 32:2536-2545
Sprague, Leslee; Lee, Joel M; Hutzen, Brian J et al. (2018) High Mobility Group Box 1 Influences HSV1716 Spread and Acts as an Adjuvant to Chemotherapy. Viruses 10:
Koster, Roelof; Panagiotou, Orestis A; Wheeler, William A et al. (2018) Genome-wide association study identifies the GLDC/IL33 locus associated with survival of osteosarcoma patients. Int J Cancer 142:1594-1601

Showing the most recent 10 out of 2602 publications